Characterization and Preliminary Safety Evaluation of Akkermansia muciniphila PROBIO

Xin Ma1, Meng Tian2, Xueping Yu1

  • 1State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.

Foods (Basel, Switzerland)
|February 10, 2024
PubMed

Insights

This study confirms the safety of Akkermansia muciniphila PROBIO as a probiotic. Rigorous testing showed no adverse effects, supporting its use in food applications.

Area of Science:

  • Microbiology
  • Toxicology
  • Probiotic research

Background:

  • Probiotics require a defined safety profile alongside health benefits.
  • A novel bacterial strain, Akkermansia muciniphila PROBIO, was isolated from human feces.

Purpose of the Study:

  • To conduct a comprehensive safety assessment of Akkermansia muciniphila PROBIO.
  • To evaluate its genotoxicity, drug sensitivity, and toxicological impact.
  • To determine its suitability for food applications.

Main Methods:

  • Assessed gastrointestinal tolerance, physiological, and biochemical traits.
  • Performed bacterial reverse mutation and in vitro mammalian cell micronucleus assays.
  • Analyzed antibiotic resistance genes, conducted acute and sub-chronic toxicity studies, and performed genome-based safety assessment.
  • Investigated moxifloxacin resistance transfer via in vitro conjugation.

Main Results:

  • Demonstrated superior gastrointestinal tolerance with no hematological or histopathological abnormalities.
  • Confirmed negative results for mutagenic, clastogenic, and toxic impacts, even at high doses.
  • Established a no-observed-adverse-effect level (NOAEL) of 6.4 × 10^11 viable bacteria.
  • Identified limited potential drug resistance and virulence genes; moxifloxacin resistance is intrinsic and non-transferable.

Conclusions:

  • Akkermansia muciniphila PROBIO exhibits a robust safety profile.
  • The strain is suitable for incorporation into food products.
  • The comprehensive safety data supports its use as a probiotic.